The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the ...
A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point ...
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors ASCO Guidelines provide ...
Recently published Acute Myocardial Infarction Market Insights report includes a comprehensive understanding of current treatment practices, acute myocardial infarction emerging drugs, market share of ...
The acute myocardial infarction market is experiencing steady growth driven by rising global cardiovascular disease prevalence and expanding geriatric populations. Advances in diagnostic technologies ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...
Gothenburg promised to optimise school admissions with a piece of code. The resulting chaos showed how unaccountable systems are ruining lives We like to imagine that injustice announces itself loudly ...
MIAMI--(BUSINESS WIRE)--OpenEvidence now integrates National Comprehensive Cancer Network ® (NCCN ®) Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) directly in answers, grounding ...
OpenEvidence now integrates National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) directly in answers, grounding responses in the pinnacle ...
OpenEvidence’s model interprets NCCN frameworks in a clinically intuitive way so that when a clinician asks a question, the most relevant NCCN algorithm is surfaced in context, alongside peer-reviewed ...
SENIOR-RITA subgroup data showed primary composite events in 37.7% with invasive therapy versus 29.4% with conservative care among frail patients (HR 1.21; 95% CI, 0.88-1.67). Cardiovascular death was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results